STAT+: The lone Democrat willing to weaken Medicare’s power to negotiate drug prices
WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s…
Category: drug prices
Regeneron is interested in obesity treatments that combat muscle loss
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Senate working group proposes 340B reforms
WASHINGTON — A bipartisan group of senators released a draft of legislation to resolve controversial…
What makes a drug a blockbuster — or a cautionary tale?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Medicare drug price negotiation’s day in court
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Novavax is on thin ice, and the latest update isn’t exactly encouraging
Want to stay on top of the science and politics driving biotech today? Sign up to…
STAT+: Biden administration makes opening offers in Medicare drug price negotiations
WASHINGTON — The Biden administration is making its opening offers to pharmaceutical companies in its…
STAT+: Judge skeptical of arguments against Medicare drug price negotiation
WILMINGTON, Del. — Today was the first time that a federal judge asked questions in-person…
Pfizer’s reset year starts with a little profit
Want to stay on top of the science and politics driving biotech today? Sign up to get…
How an immunological Trojan horse could treat disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
23andMe breach targeted Chinese, Jewish populations
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Merck, Johnson & Johnson CEOs agree to testify in Congress on high drug prices, avoiding Bernie Sanders’ subpoena
WASHINGTON — Merck CEO Robert Davis and Johnson and Johnson CEO Joaquin Duato have agreed…
Eli Lilly overtakes Tesla in market value
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Merck CEO refused to testify in Senate because he’s not an expert in drug pricing, Bernie Sanders says
WASHINGTON — Sen. Bernie Sanders on Thursday jabbed the CEO of Merck for telling congressional…
Another step toward new drugs for Parkinson’s
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Lilly’s gene therapy restores hearing in an 11-year-old, paving way for more treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Ahead of Medicare drug price reform, pharma’s drug pricing has a Streisand effect
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharma’s attack on Medicare drug price negotiation might benefit Biden
WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program…
Investigators fault Lilly plant for manufacturing issues
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The Senate health committee looks into its first subpoena in 40 years
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
STAT+: Bernie Sanders proposes subpoenas of CEOs of J&J, Merck on drug prices
WASHINGTON — Senate health committee chair Bernie Sanders has taken a step toward subpoenaing the…
The XBI comedown after JPM
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Copay coupons for some drugs must count toward deductibles, after Biden court move
WASHINGTON — Insurers will have to count drug copay coupons toward deductibles and patient spending…
The big any-day-now biotech news we’re keeping an eye on
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The four biotech stories you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: The new NIH director is walking a tightrope on Biden’s drug pricing vision
WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally…
Novartis reportedly decides to pass on Cytokinetics
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The highs — and lows — of JPM 2024 you should pay attention to
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
STAT+: Courts will decide the future of Medicare’s power to negotiate drug prices within months
WASHINGTON — Pharmaceutical companies’ efforts to scuttle President Biden’s signature health care achievement, empowering Medicare…
JPM Day 3 had a cautiously optimistic outlook
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
Anthony Fauci talked Covid in Congress in a nine-hour, closed-door grilling — and that was just day one
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: HHS’s Xavier Becerra, once an ‘invisible’ secretary, is racing to cement a clearer legacy
WASHINGTON — He’s been called the “invisible” secretary. So far removed from the White House…
This is the TLDR of JPM Day 1
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
.jpg)
STAT+: Florida faces ‘complicated road’ before actually importing drugs from Canada, expert says
Last week, the Food and Drug Administration granted Florida permission to import medicines from Canada,…
STAT+: Sen. Sanders, others lawmakers open probe into asthma inhaler makers over pricing, patent maneuvers
Several U.S. lawmakers including Sen. Bernie Sanders (I-Vt.) are investigating the prices charged by four…
Biden’s FDA is letting Ron DeSantis import cheaper drugs from Canada. Who gets to take credit?
WASHINGTON — The Biden administration has approved Florida Gov. Ron DeSantis’ plan to import a…
STAT+: GSK is replacing its popular Flovent inhaler with authorized generics, raising cost concerns for asthma patients
As of Jan. 1, thousands of asthma patients in the U.S. will no longer be…
At JPM, how much health policy talk should we expect?
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Why CG Oncology will be the first test of 2024’s IPO waters
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Anavex’s slow journey to failure
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: 3 health policies states are taking on in 2024
For most states, the new year means a new legislative session. STAT’s taking a look…
STAT+: Venture capital is still pouring into drug research despite Medicare price negotiation
WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s…
Morning Rounds: Our newsroom’s favorite stories of 2023
Understand how science, health policy, and medicine shape the world everyday. Sign up for our…
The clock is ticking, and cytokinetics is running out of December
Want to stay on top of the science and politics driving biotech today? Sign up to get…
BioMarin appeases an activist
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The biotech updates you need to read today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: The Biden administration’s plan to use march-in rights to address drug prices would kill future world-changing innovations
The Bayh-Dole Act is widely credited with kickstarting a new era of American innovation involving the…
FDA chastens pet companies over antibiotics
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Is it time to worry about Moderna?
Want to stay on top of the science and politics driving biotech today? Sign up to get…